TK cell therapy

Update on Talaris’ Phase 2 Study of FCR001 in Living Donor Kidney Transplant Recipients to be Presented at ATC Virtual Congress

Retrieved on: 
Friday, May 29, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Medicine, Medical specialties, Clinical medicine, Organ transplantation, Transplantation medicine, Kidney transplantation, Immunosuppression, Therapy, TK cell therapy, FCR001, Talaris Therapeutics

The data show that 26 of 37 (70%) of LDKT recipients of FCR001 were able to be weaned off all of their immunosuppression treatments.

Key Points: 
  • The data show that 26 of 37 (70%) of LDKT recipients of FCR001 were able to be weaned off all of their immunosuppression treatments.
  • The degree of HLA mismatch (spanning 0/6 to 6/6) between the donor and the recipient did not affect either the safety or the efficacy of the therapy.
  • FCR001 has received both Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration.
  • A Phase 3 trial of FCR001 in living donor kidney transplant recipients is now enrolling patients.

Incysus Therapeutics Treats First Patient in Phase 1 Study of Gamma Delta (γδ) T Cell Immunotherapy in Leukemia and Lymphoma Patients Undergoing Allogeneic Stem Cell Transplantation

Retrieved on: 
Tuesday, May 12, 2020
Medical specialties, Medicine, Clinical medicine, Transplantation medicine, Graft-versus-host disease, Leukemia, TK cell therapy, T-cell depletion

T cells have been shown to be key both in the response to leukemia and in GvHD.

Key Points: 
  • T cells have been shown to be key both in the response to leukemia and in GvHD.
  • Incysus Therapeutics has developed this novel T cell approach to allow haploidentical transplantation while providing immune protection to prevent leukemic relapse and infections during the period in which the patient recovers.
  • I am pleased that our team has successfully initiated patient enrollment in a second Phase I study.
  • However, relapse of the blood cancer for which the patient received the transplant occurs in half of the patients undergoing this procedure.